Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/9261
Title: | Clostridium scindens metabolites trigger prostate cancer progression through androgen receptor signaling |
Authors: | Bui, Ngoc-Niem Li, Chen-Yi Wang, Ling-Yu Chen, Yu-An Kao, Wei-Hsiang Chou, Li-Fang |
Keywords: | Clostridium scindens Bacterial metabolite Prostate cancer Androgen |
Issue Date: | Apr-2023 |
Publisher: | Elsevier Taiwan LLC |
Citation: | Original Article |
Abstract: | Abstract Prostate cancer (PCa) is one of the most common malignancies in men; recently, PCa-related mortality has increased worldwide. Although androgen deprivation therapy (ADT) is the standard treatment for PCa, patients often develop aggressive castrationresistant PCa (CRPC), indicating the presence of an alternative source of androgen. Clostridium scindens is a member of the gut microbiota and can convert cortisol to 11b-hydroxyandrostenedione (11b-OHA), which is a potent androgen precursor. However, the effect of C. scindens on PCa progression has not been determined. In this study, androgen-dependent PCa cells (LNCaP) were employed to investigate whether C. scindens-derived metabolites activate androgen receptor (AR), which is a pivotal step in the development of PCa. Results showed that cortisol metabolites derived from C. scindens-conditioned medium promoted proliferation and enhanced migration of PCa cells. Furthermore, cells treated with these metabolites presented activated AR and stimulated AR-regulated genes. These findings reveal that C. scindens has the potential to promote PCa progression via the activation of AR signaling. Further studies on the guteprostate axis may help unravel an alternative source of androgen that triggers CRPC exacerbation |
URI: | http://localhost:8080/xmlui/handle/123456789/9261 |
Appears in Collections: | VOL 56 NO 2 2023 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
246-256.pdf | 2.22 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.